Using this administration route, Cantarini et al. described the pharmacokinetic patterns of the EGFR TKI gefitinib in healthy volunteers, and Chiu et al. studied the pharmacokinetics of dacomitinib (pan-HER TKI) in patients with locally advanced head and neck squamous cell carcinoma [23, 24]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.